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A B S T R A C T
Central venous catheters are indispensable for the long-term treatment of seriously and chronically ill
patients, but their use is often associated with a variety of complications; indeed, 90% of primary
bloodstream infections are related to patients having a catheter. In studies performed in France,
Germany and Italy, meticillin-resistant Staphylococcus aureus (MRSA) accounted for>50% of all S. aureus
isolates obtained in catheter-related bloodstream infections (CRBSIs). These infections have a serious
impact on long-term disability of the patient, a substantial additional financial burden for health
systems, and high costs for patients. Decreasing the rate of CRBSIs requires amultidisciplinary approach,
including behavioural and educational interventions and the insertion of the correct type of catheter.
Although vancomycin remains the cornerstone of empirical therapy for CRBSIs caused by MRSA,
combination of different antimicrobials and new approaches are indispensable to enhance the
eradication of S. aureus biofilms and to manage the patient appropriately.
 2013 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All
rights reserved.Contents
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Biofilm production is a successful strategy for microbial
survival and for the establishment of infection. Since host defence
mechanisms and response to antimicrobials are severely pre-
judiced against bacteria living in the biofilm ‘microniche’, chronic
infections and sepsis related to biofilms represent a major concern
in nosocomial settings.ction and Cancer. Published by Elsevier Ltd. All rights reserved.
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vascular access devices with a wide range of clinical applications,
are disposed to biofilm infection because they offer a favourable
surface for bacterial attachment [1].
Staphylococci are recognised as the most frequent bacteria
responsible for biofilm-associated infections, and the involvement
in catheter-related infections of meticillin-resistant Staphylococcus
aureus (MRSA) has increased the challenge for the healthcare
community [2,3].
Upon insertion into the patient, the surface of the catheter
is quickly coated with host-derived matrix proteins such as
fibrin, fibrinogen, fibronectin, collagen, elastin and laminin [4,5],
which serve as scaffolding for bacteria that may have passed the
skin barrier. S. aureus can bind to the catheter surface owing to a
wide range of cell-wall surface proteins that possess binding
domains for the host matrix, and such surface proteins are
referred to as microbial surface components recognising
adhesive matrix molecules (MSCRAMMs) [6]. Indeed, micro-
organisms can start to colonise the medical device, forming
biofilm, as early as 24 h after catheter placement [7], and
bacteria may then flow into the systemic circulation resulting in
a bloodstream infection (BSI).
Thus, although CVCs are indispensable for long-term treatment
of seriously and chronically ill patients, their use is often associated
with a variety of complications; indeed, 90% of primary BSIs are
related to patients having a central line catheter [8,9].
Although there is debate about whether catheter-related
BSIs (CRBSIs) are an independent risk factor for mortality, it is
clear that these infections have a serious impact on long-term
disability of the patient, a substantial additional financial burden
for health systems, and high costs for patients and their families
[10–12].
2. Inside catheter-related bloodstream infections: definition,
pathogenesis and epidemiology
A CRBSI is clinically defined as ‘systemic blood infection
(bacteraemia) where the same microorganism is retrieved from
both the blood and the catheter, without evidence of infectionwith
the identical organism at any other site in the body’ [13]. The most
common routes for CVC contamination are migration of skin
micro-organisms at the catheter insertion site along its surface
tract, with subsequent colonisation of the catheter tip, and direct
contamination of the catheter hub by contact with hands,
contaminated fluid or devices. Less commonly, catheters might
be contaminated haematogenously from another focus of infection
[14].
From a nationwide surveillance study among 49 US hospitals
over a 7-year period, it has been highlighted that the most
frequent pathogens for CRBSIs were coagulase-negative staphy-
lococci (31%), S. aureus (20%), enterococci (9%) and Candida spp.
[15]. MRSA has become a concern in recent years in the USA,
Europe and Japan owing to its increasing rate and, although it
appears to have stabilised or even decreased in some European
countries (Austria, Cyprus, Estonia, France,Greece, Ireland and the
UK), it remains a public health priority since its proportion is still
>25% in more than one-third of the reporting countries [16,17]
and because among the staphylococci, meticillin-resistant iso-
lates have been the most commonly reported as responsible for
nosocomial BSIs [18,19].
Although the incidence of CRBSIs has recently decreased as a
result of strict prevention efforts, S. aureus has been reported as one
of the most frequently reported pathogens in intensive care unit
(ICU)-acquired infections (21.8%) in studies performed in France,
Germany and Italy [20,12], and MRSA accounted for >50% of all S.
aureus isolates obtained in ICU CRBSIs [21].3. Biofilm
Biofilm formation is awinningmove formicro-organismswith
respect to the planktonic lifestyle because its enables bacteria to
adapt to altered environmental conditions and provides shelter
from the host immune system (i.e. phagocytic elimination,
opsonisation) and from antimicrobial/antifouling compounds
[22].
Generally, biofilm development occurs via a mechanism
termed ‘quorum sensing’ in which the expression of specific
signal molecules, called ‘autoinducers’, is regulated in response
to cell density and stressed environmental conditions [23].
S. aureus is able to produce a heterogeneous multilayered
biofilm using different strategies, including: (i) expression of
numerous surface proteins, including Bap, SasG, FnBPs or Spa;
(ii) release of extracellular DNA (eDNA); and (iii) expression of
the polysaccharide intercellular adhesin (PIA) by the icaADBC
operon [24].
Biofilm development is a complex mechanism and includes
different stages that can differ from organism to organism. The
steps of S. aureus biofilm production on intravenous (i.v.)
catheters can be summarised as follows: (i) attachment to the
catheter surface through electrostatic and hydrophobic forces,
platelet binding and shear stress from the fluid environment
cause attachment to the host matrix through MSCRAMMs; (ii)
intercellular adhesion and growth of the bacteria into sessile
multicellular communities through excretion of specific poly-
mers; and (iii) detachment and dissemination of new divided
cells to colonise other surfaces and to prevent density-derived
starvation within the mature biofilm. Thus, biofilm embedded
micro-organisms live in a self-producing exopolymeric matrix or
‘slime’ that alters the global micro-organism phenotype with
respect to growth rate, gene expression and response to external
attacks [25].
Nutrients and oxygen permeate the matrix through specific
channels and the resulting gradient may generate a population of
cells that differ substantially in their metabolism [26]. These
cells, named ‘persisters’, have a low metabolic rate and live in a
dormant state attributable to starvation and a low oxygen
concentration in the environment, conditions that cause high
tolerance to antibiotics [27]. However, persisters are not
mutants; indeed, re-culturing of persisters produces a wild-type
population with a new population of persisters [28,29]. In other
words, persisters are stationary phase cells with increased
resistance to killing owing to slow growth produced not only
in biofilms but also in stationary phase planktonic populations
[30].
Moreover, antibiotic penetration through the biofilm is limited
by the exopolysaccharide matrix that acts like a diffusion barrier,
limiting the antibiotic uptake rate and also reacting with these
molecules [25]. For a long time it appeared that molecular weight
was a limiting factor for antibiotic penetration into biofilms,
however recent studies have demonstrated that the molecular
dimensions of antibiotics have no significant relevance [31,32].
Indeed, in an in vitro study by Stewart et al., daptomycin, one of the
antibiotics with a higher molecular weight, was confirmed to have
freely diffusive penetration into a large, dense cluster of
staphylococcal biofilms [33].
Thus, from a clinical point of view, the hallmark of biofilm-
embedded micro-organisms is their resistance to large doses of
traditional antimicrobial agents; they can actually be 100–1000-
fold less susceptible than their planktonic counterparts [34]. For
this reason, treatment of CRBSIs, which is regulated by standar-
dised antimicrobial susceptibility tests performed with planktonic
cells, can have an unsuccessful outcome and often relies on
removal of the catheter [22].
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Although there is no unanimously accepted clinical pathway for
the management of CRBSIs, several guidelines and recommenda-
tions have recently been published [34–37] and, in general,
treatment of these infections should include oral or i.v. antibiotics
or an antibiotic lock technique (ALT) and removal and re-insertion
of the CVC in the case of S. aureus infection.
It is important to underline that the vast majority of S. aureus
biofilm infections require long-term therapy and so it is crucial to
take into account toxicities and drug interactions when selecting a
specific regimen.
The ability of an antibiotic to eradicate MRSA embedded in
biofilm depends on many factors such as its molecular mass, net
charge, permeability coefficient and bactericidal activity. Anti-
biotics of low molecular weight are likely to diffuse more
efficiently into the biofilm [38].
So, when considering staphylococcal biofilm treatment options,
the ideal therapy would have several characteristics: bactericidal activity against slow-growing, stationary phase-like
cells; low rate of resistance development;
 straightforward administration of the therapy to patients, with
few side effects; and broad efficacy against all staphylococci and polymicrobial
biofilm infections.
Even if the catheter has been removed and a new one has been
inserted, an antibiotic regimen including antibiofilm activity must
be considered. Indeed, colonisation of the new catheter by biofilm
fragments dislodged from the one that has been removed is
possible.
4.1. Current therapies
For the treatment of serious MRSA device-related infections,
vancomycin remains the cornerstone of empirical therapy, but in
the most recent 10 years S. aureus minimum inhibitory concen-
trations (MICs) to vancomycin have increased from 0.25 mg/L to
2 mg/L, associating its use with several therapeutic failures.
Guidelines indicate that patients with complicated MRSA
infections should receive 4–6 weeks of vancomycin therapy,
except thosewith a vancomycinMIC > 2 mg/L, who should instead
receive daptomycin or linezolid depending on susceptibility data
[38].
Vancomycin acts by binding to the cell wall peptidoglycan
chains and therefore preventing the cross-linking step during cell
wall synthesis. This effect leads to a weakened cell wall, slowing
growth and bacterial death [39].
Although vancomycin is considered bactericidal, its time-
dependent mode of action, the i.v. administration required and
the frequent side effects are serious limitations of this drug that
can lead to longer hospital stays and higher costs for the institution
[40].
Moreover, recently there have been conflicting results on the
use of vancomycin monotherapy in the treatment of biofilm-
embedded MRSA [41–43]. Rose and Poppens demonstrated that
vancomycin exhibited bactericidal activity towards planktonic
MRSA cells at low levels (1mg/mL), but the MIC increased four- to
eight-fold in a biofilm susceptibility assay, suggesting its use in
combination with rifampicin or tigecycline [44]. In fact, also in
other studies it has been shown that vancomycin efficacy increases
in combination with other antibiotics (rifampicin, gentamicin,
clindamycin), leading to better penetration of the drug into the
depth of the biofilm [45,46].In the face of emerging resistance to vancomycin and other
glycopeptides, daptomycin is being used as an alternative first-line
therapy against biofilm-embedded MRSA.
Daptomycin, a cyclic lipopeptide, is bactericidal towards log
phase, stationary phase and metabolically inert Gram-positive
bacteria owing to insertion of its lipophilic tail into the cell
membrane, resulting in membrane depolarisation and cell death.
In a study by Mascio et al., daptomycin demonstrated bactericidal
activity against log phase S. aureus cells at low concentrations
(2 mg/L) and against stationary phase cells at a higher concentra-
tion (100 mg/L) [47].
For the treatment of staphylococcal biofilm infections, dapto-
mycin alone is more effective than other monotherapies. An in
vitro study of 12 MRSA clinical isolates showed that daptomycin
was the most effective of five antibiotics tested (compared with
clindamycin, linezolid, tigecycline and vancomycin) at killing cells
within biofilms; in fact, although total killing of biofilm cells was
not achieved, daptomycin treatment eliminated 96% of biofilm-
associated bacteria [43].
In combination therapy, daptomycin treatment with rifampi-
cin or gentamicin has shown conflicting results, but its clinical use
has proven successful against several forms of biofilm infections
[48,49]. Finally, in a rat model study by Van Praagh et al.,
combined daptomycin ALT and systemic dosing resulted in
clearance of S. aureus CVC-related infection after two daily ALT
treatments [50].
Oxazolidinones inhibit ribosome function and prevent protein
synthesis by targeting the assembly of ribosomal subunits.
Linezolid is the only oxazolidinone approved for clinical use
[51] and has encouraging properties, including broad-spectrum
activity against Gram-positive bacteria, good tissue distribution
and penetration, and bioavailability. Moreover, among the
antibiotics used for the treatment of invasive MRSA infections,
linezolid is one of the few that can be taken orally. Linezolid has
demonstrated activity against biofilms both in in vitro and in vivo
model systems. In a rabbitmodel of S. aureus endocarditis, linezolid
cleared biofilm vegetations after 5 days of treatment when
administered at high doses that maintained the blood level above
the MIC [52], whilst in another recent study linezolid exhibited
bactericidal activity in combinationwith rifampicin and prevented
the development of infection at secondary sites [53].
Linezolidwas also tested on staphylococcal biofilms utilising an
in vitro pharmacokinetic model in which the biomass was
developed on a cellulose filter and this was perfused with a
solution containing the antibiotic. This study highlighted that
linezolidwas very effective at clearing biofilm if the infected device
was exposed to the antibiotic for longer time periods, whilst
success with short-term exposure varied and might be dependent
on the type of infected device being treated [54]. In addition, a
model of ALT gave conflicting results, showing that the amount of
biofilm remaining after 5 days of linezolid exposure was similar to
negative controls [55]. Instead, clinical use and combination
therapy of linezolid to treat staphylococcal biofilm infections has
been shown to be promising. In a study of prosthetic joint
infections, treatment of patients (49 total) with combined therapy
of linezolid and rifampicin cleared infection with a success rate of
nearly 70% without implant removal [56].
Rifampicin has the capacity to kill metabolically dormant
sessile bacteria, typical of biofilm, and has the ability to effectively
penetrate the biofilm layer preventing its formation within only
minutes of treatment. It has bactericidal activity and targets the
bacterial RNA polymerase, inhibiting RNA synthesis. Numerous
examples of in vitro studies, in vivo animalmodels of infection, and
clinical studies demonstrated the efficacy of rifampicin in treating
staphylococcal implant infections [57]. In one study evaluating
antibiotics within ALT, co-administration of rifampicin with other
Table 1
Modifiable risk factors for catheter-related bloodstream infections (CRBSIs).
Aseptic measures Risk of infection declines following standardisation
of aseptic care
CVC duration Length of stay increases the risk of CRBSIs more
than other risk factors
CVC insertion site Insertion site increases the infection risk relative
to the density of local skin flora and the chance
of developing thrombophlebitis
Type of catheter CVCs can be chosen with regard to material and
whether or not to use an antimicrobial/
anti-infective-coated catheter
Nurse-to-patient ratio Education and training of nurses are critical for
the prevention of CRBSIs
CVC, central venous catheter.
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more than any monotherapy.
The same study demonstrated that daptomycin, minocycline
and tigecycline were more effective in decreasing viable biofilm-
embedded MRSA after 24 h of exposure than linezolid or
vancomycin. Addition of rifampicin to vancomycin or linezolid
was synergistic against biofilm-embedded MRSA [55]. In addition
to its bactericidal and fast-acting properties, rifampicin has good
pharmacokinetic properties, achieving penetration into diverse
tissue sites. It is lipid soluble, facilitating passage through
biological membranes, perhaps improving its biofilm-penetrating
capability.
Fosfomycin has been characterised in previous in vitro studies
as an effective antibacterial against MRSA [58,59]; however, no in
vivo studies on the effects of fosfomycin on biofilm-embedded
MRSA have been published.
A recent study evaluated the activity of several anti-MRSA
compounds, alone and in combination with fosfomycin, on
bacterial colony counts in biofilm and demonstrated that
fosfomycin enhances the activity of linezolid, minocycline,
vancomycin and teicoplanin on MRSA in biofilm, even more than
rifampicin combination regimens. The low molecular weight of
fosfomycin may partially explain its enhanced antibacterial
activity against biofilm-embedded micro-organisms [60].
4.2. New therapeutic approaches
Essential antimicrobial targets for inhibition of biofilm forma-
tion or for eradication of mature biofilm are not only the bacteria
themselves but also destruction of biofilmmatrix and interference
with the biofilm signalling system [61].
Whilst antibiotics and novel derivatives have been themainstay
of empirical therapy, many efforts have been made to design more
innovative therapeutic options such as nanosilver, the cytokine
interleukin-12, nitric oxide or antistaphylococcal phages [62–65].
However, the clinical utility of these agents has yet to be
demonstrated. One strategy for controlling biofilm growth is to
weaken its structure by targeting the matrix components, which
leads to dispersal of bacteria and consequently to a greater
susceptibility to antibiotics [66].
5. Prevention of catheter-related bloodstream infections
Decreasing the rate of CRBSIs requires a comprehensive and
multidisciplinary approach, including behavioural and educational
interventions of the hospital staff as well as the use of new
technologies. There are several guidelines providing recommenda-
tions for the preventions of CRBSIs [67,68]. These guidelines
examine the usefulness of various practices such as the choice of
CVC, site of insertion, observance of an adequate aseptic technique,
care and replacement of the catheter, and the choice of appropriate
antibiotic therapy.
An initial and crucial step in preventing CRBSIs is to weight and
consider the risks and benefits of using a CVC in order to avoid
unnecessary placements; indeed, in a recent hospital survey it was
calculated that among a total of 378 CVCs inserted in 292 patients,
accounting for 2704 catheter-days, 130 catheter-days (4.8%) were
unnecessary, with a higher proportion in non-ICU settings (6.6%)
[69]. Various risk factors involving insertion or catheter handling
have been described in the literature. Such risk factors have been
named ‘modifiable’ [70] because they are the optimal candidates
for CRBSI prevention strategies (Table 1).
These factors are as follows. (i) Aseptic measures: hygiene and
aseptic techniques during placement, management and removal of
catheters are essential in preventing infection. (ii) CVC duration:
the overall proportion of CRBSIs is actually higher in long-termdevices, and the length of stay in ICU settings increases the risk of
CRBSImore than other risk factors [71]. (iii) CVC insertion site [72]:
the site at which a catheter is placed influences the subsequent
possibility for a catheter-related infection risk in terms of density
of local skin flora and chance of developing thrombophlebitis. In
some retrospective studies, catheters inserted into an internal
jugular vein have usually been associated with a higher risk of
CRBSI than those inserted into a subclavian site [73]. Femoral
catheters have, on the other hand, been associated with a higher
risk for venous thrombosis than internal jugular or subclavian
catheters [74]. (iv) Introduction of the correct type of catheter. And
(v) high workload: an optimum nurse-to-patient ratio has been
correlated with a lower CRBSI rate [70].
5.1. Behavioural interventions and educational programmes
Performing hand hygiene procedures before insertion or
maintenance of a catheter is the first and most important basic
rule of hygiene and, combined with proper aseptic techniques
during catheter manipulation, provides protection against
infection.
Reports in past years have clearly demonstrated that the risk
of infection declines following standardisation of aseptic care
[75–77]. Maximal sterile barriers, which include wearing a mask,
cap, sterile gown and sterile gloves and covering the insertion site
with a large surgical drape, were shown to be effective either
alone or as a part of a multimodal CRBSI prevention strategy.
These CRBSI bundles were, as reported in many published
studies, very efficient and reduced the CRBSI incidence density,
reported as the number of CRBSI episodes per 1000 catheter-
days, by 70% [78].
Education, training and staffing are critical for the prevention of
CRBSIs. Well organised programmes include education of health-
care personnel and periodically assessing knowledge of the
guidelines for all personnel involved in the insertion and
maintenance of catheters.
Recently, an educational programme demonstrated that a 1-
day course on basic infection control practises and a demonstra-
tion of insertion both of arterial and CVCs illustrated to beginning
post-graduate year 1 (PGY-1) physicians resulted in a significant
reduction in CRBSI and primary BSIs from 3.3 to 2.4 per 1000 CVC-
days [75]. Other recent studies demonstrated that specialised ‘IV
teams’ have shown clear helpfulness in reducing the CRBSI
incidence, associated complications and overall costs [79,80].
Although educational programmes have an impact on the
healthcare institution and may not be sustainable over time,
hospitals should try to provide clear guidelines for catheter
insertion and maintenance and ensure their observance to
maintain a high level of awareness of standard procedures [81].
The benefits of preventing CRBSIs are numerous, and if we think
that a large proportion of them are preventable, it is clear that a
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face this problem.
5.2. Choice of the correct central venous catheter (material and
antiseptic/antimicrobial-coated catheters)
In recent years, significant efforts have been made to design
new catheters aimed at reducing the risk of CRBSIs.
Major choices for the clinician when inserting a CVC are
regarding its material and whether or not to use an antimicrobial/
anti-infective-coated catheter.
Regarding the material, important considerations have been
made on this topic, i.e. polytetrafluoroethylene (Teflon1) or
polyurethane catheters have been associatedwith fewer infectious
complications than catheters made of polyvinyl chloride or
polyethylene [82]. Catheter material is critical in the prevention
of CRBSIs; it should be biocompatible/biostable, chemically
neutral, and drug/sterilisation proof [83].
The underlying principle for the use of a coated CVC is the
possibility ofmodifying the catheter surface tominimise bacterial
adhesion and consequently biofilm formation. The decision to
insert an antibiotic-coated CVC has to be taken in view of the
single risk factors for an infection of a given patient and overall
rates of CRBSI for a specific hospital. Following the US Centers for
Disease Control and Prevention (CDC) Healthcare Infection
Control Practices Advisory Committee guidelines, coated cathe-
ters should be inserted in adult patients if the CVC is to remain
place for >5 days as well as in institutions with high CRBSI rates
[67].
Coated CVCs are available with different impregnated
materials: (i) chlorhexidine and silver sulfadiazine (CSS); (ii)
minocycline–rifampicin (MR); and (iii) silver in a carbon/
platinum (SPC) matrix. One meta-analysis and one randomised
controlled trial have demonstrated that first-generation CSS
catheters, which are coated only on the external luminal surface,
are associated with a reduced risk of CRBSI compared with
standard non-coated catheters. In fact, chlorhexidine and silver
salts act synergistically, disrupting the cytoplasmic membrane
and increasing silver uptake, which is extremely toxic for micro-
organisms [84,85].
Second-generation CSS catheters are now available with
chlorhexidine also coating the internal surface, but a limited
number of control trials have been carried out [86,87]. CSS
catheters are more expensive than standard catheters, however
there is a debate on the real cost saving per catheter despite
adherence to other preventive strategies; one study showed that
CSS catheters could lead to a cutback per catheter in settingswith a
high CRBSI rate ranging between US$391 and US$68 [88].
MR CVCs have broad-spectrum activity and have been studied
both in vitro and in vivo in randomised clinical trials, which have
demonstrated that these catheters are effective against biofilm-
producing bacteria and are associated with a lower rate of CRBSIs
[89,90].
Compared with first-generation CSS catheters, MR CVCs have
also been found to be related to lower CRBSI rates, but their
evaluation against second-generation CSS CVCs has to be further
investigated. Although no MR-resistant organisms were reported
in several studies [91–93], there are still some concerns about the
potential for development of rifampicin-resistant bacteria. Finally,
several studies revealed that these catheters are associated with
superior cost saving compared with standard catheters [94] and
with first-generation CSS CVCs [95,96].
SPCs are only available in the USA and some studies have
evaluated their effectiveness against uncoated orMR catheters, but
their association with a lower rate of CRBSIs has not yet been
clearly demonstrated [97].5.3. Catheter antibiotic lock therapy
Given the cost, difficulty and complication associated with the
removal of a long-term CVC, some guidelines have suggested the
use of catheter ALT for the prevention of CRBSI and salvage of the
CVC in high-risk patients [38,98].
ALT consists of the ‘lockage’ of a specified antibiotic in the CVC
when the catheter is not in use (generally 18–24 h)with orwithout
heparin at concentrations 100–1000 times higher than the target
micro-organism’s MIC measured for systemic therapy. The
recommended duration of ALT is 2 weeks [99].
Ideally, the use of concentration-dependent killing antibiotics is
optimal, rather than time-dependent killing antibiotics such as
glycopeptides, so that minimum biofilm eradicating concentra-
tions can be achieved without dependence on dwell time.
Whilst ALT has been shown to decrease the rate of CRBSIs in
haemodialysis patients with long-term catheters, the benefit in
ICU patients with short-term CVCs is less clear [98].
More rigorous clinical studies are needed before antibiotic lock
solution can be universally recommended, in part because of the
concern for the generation ofmultidrug-resistantmicro-organisms
[99]. Choosing the correct ALT prevention treatment is crucial
because the agent selected has to be able to penetrate the thick
biofilm matrix and act against microbial cells growing in a
stationary-like state.
6. Health economic aspects of the problem
Use of a medical device is the greatest exogenous predictor of
healthcare-associated infection (HAI), and CRBSIs, together with
surgical-site infections, ventilator-associated pneumonia and
catheter-associated urinary tract infections, account for approxi-
mately three-quarters of HAIs [100].
Although global estimations of HAIs are not available, by
integrating data from several published studies it is clear that
hundreds ofmillions of patients are affected every yearworldwide,
with the burden of disease much higher in low- and middle-
income countries [101].
Recent data regarding the costs and numbers of HAIs are
available from the European Centre for Disease Prevention and
Control (ECDC), which has calculated that HAIs involve 4.1 million
patients annually in the European Union; furthermore, as reported
by theWorld Health Organisation (WHO) in 2011, only direct costs
associatedwithHAIs account for abouts7 billion annually [16,18].
In particular, it is important to underline that MRSA accounts
for 44% (n = 171 200) of these HAIs and causes 22% (n = 5400) extra
deaths and 41% (n = 1 050 000) extra days of hospitalisation, with
extra attributable in-hospital costs of ca. s380 million annually
[16].
The CDC has recently estimated the annual hospital costs of
HAIs in the USA to be between US$28 billion and US$45 billion per
year [34], and MRSA-associated costs are ca. US$10 billion/year,
occurring in 31.3/100 000 hospitalised people, 20% of which result
in fatal infections [102].
As the use of CVCs has increased over the last years, so the
number of CRBSIs has risen [103]. It has been estimated that in the
USA over 5 million medical devices are used per annum and ca. 4%
of patients develop CRBSI; the number of deaths has been
estimated at 12.5%, equating to 0.5% of CVC insertions [104].
The problem is even more serious among ICUs where in the ca.
250 000 CRBSIs occurring every year in the USA, ca. 28 000 lead to
deaths in ICU patients only, with an annual cost of up to
US$2.3 billion [105].
Furthermore, as reported by Tacconelli et al. in a study
performed among four European countries, additional length of
hospital stay per CRBSI episode varies between 4 days and 14 days,
S. Esposito et al. / Journal of Global Antimicrobial Resistance 1 (2013) 71–7876with additional associated costs from s4200 to s13 030 per
episode, representing an annual cost to the national healthcare
systems of between s53.9 million in the UK and s130 million in
France [106]. Nevertheless, it should be underlined that cost-
effectiveness studies might be of limited value because sometimes
they lack precision and do not have large economic perspectives,
resulting in poor quality reports. For instance, cost reports of a
single episode of CRBSI in the literature vary between US$3000 and
US$56 000, hence data from different types of analyses must be
interpreted with caution [10,11,107].
Usually three key components should be included in a complete
global socioeconomic cost analysis of HAIs: direct medical costs
that directly impact hospital finances; indirect costs (related to
productivity); and non-medical costs or intangible costs related,
e.g. to the diminished quality of life of the patient. In a 2-year,
prospective, case–control study, Tarricone et al. evaluated direct
healthcare costs of central line-associated BSIs according to a
microcosting approach and found not only that central line-
associated BSIs pose a significant increase in utilisation of hospital
resources but also that the use of innovative and relatively simple
technologies, in this case closed infusion containers, can signifi-
cantly reduce the incidence of HAIs without additional weight on
the overall hospital budget [108].
From these numbers, not only the magnitude of the CRBSI
burdenworldwide but also the need to urgently establish a reliable
system for healthcare-associated infection and CRBSI surveillance
to gather data on the actual numbers and costs as frequently as
possible is clear. Moreover, evaluation of the key determinants of
CRBSIs is an essential step to identify strategies and measures for
prevention. In fact, robust evidence supports that CRBSIs can be
prevented and the burden reduced by as much as 50% [109].
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